For Immediate Release
Media Contact: Bob Cooper
Date: May 22, 2006
Idaho Receives $198,000 from Lupron Settlement
(Boise) – The State of Idaho has received $198,000 from a settlement agreement involving the prescription drug Lupron, Attorney General Lawrence Wasden said. Lupron is used to treat prostate cancer, endometriosis, and early puberty. The settlement with manufacturer TAP Pharmaceutical Products, Inc. resolves potential claims regarding the pricing of the drug, and does not involve the safety of the drug.
“If you purchased Lupron or if you are the heir of someone that purchased Lupron, you may be entitled to a refund,” Attorney General Wasden said. “Refunds may be up to $100 or 50 percent of the consumer’s out of pocket expense, whichever is greater.”
Consumers who purchased Lupron may access the claim form on Attorney General Wasden’s website.
The deadline to submit a claim is July 24, 2006.
“The money will be used to reimburse consumers who purchased Lupron and did not file a claim in the national class action lawsuit,” Wasden said.
Idaho consumers will be reimbursed from the $198,000. Money not claimed by consumers will be used to support the Idaho Comprehensive Cancer Control Program, a new program run by the Idaho Bureau of Community and Environmental Health, a division of the Idaho Department of Health and Welfare.
The State of Idaho will receive compensation in addition to the settlement for certain purchases of Lupron by its agencies and universities.
- End -